Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Nicol Keith

Showing results (11-20 of 61) with videos related to

Pageof 7
Sort By:
Nature Clinical Practice. Oncology|November 3, 2005
Drug insight: Cancer cell immortality-telomerase as a target for novel cancer gene therapiesW Nicol Keith, Alan Bilsland, Maryon Hardie, et al.
Expert Reviews in Molecular Medicine|February 28, 2004
Telomerase-directed molecular therapeuticsW Nicol Keith, Alan Bilsland, T R Jeffry Evans, et al.
Cancer Research|September 6, 2005
Lack of telomerase gene expression in alternative lengthening of telomere cells is associated with chromatin remodeling of the hTR and hTERT gene promotersStuart P Atkinson, Stacey F Hoare, Rosalind M Glasspool, et al.
Cancer Research|February 3, 2006
Transcriptional repression of telomerase RNA gene expression by c-Jun-NH2-kinase and Sp1/Sp3Alan E Bilsland, Katrina Stevenson, Stuart Atkinson, et al.
Oncogene|July 2, 2003
Profiling, comparison and validation of gene expression in gastric carcinoma and normal stomachKarin A Oien, J Keith Vass, Ian Downie, et al.
Regenerative Medicine|May 1, 2007
Telomerase promoter reprogramming and interaction with general transcription factors in the human mesenchymal stem cellNedime Serakinci, Stacey F Hoare, Moustapha Kassem, et al.
Neoplasia (New York, N.Y.)|July 23, 2005
The hTERT and hTERC telomerase gene promoters are activated by the second exon of the adenoviral protein, E1A, identifying the transcriptional corepressor CtBP as a potential repressor of both genesRosalind M Glasspool, Sharon Burns, Stacey F Hoare, et al.
Drug Discovery Today|August 21, 2007
Seeding drug discovery: integrating telomerase cancer biology and cellular senescence to uncover new therapeutic opportunities in targeting cancer stem cellsW Nicol Keith, Catherine M Thomson, Jill Howcroft, et al.
Biochimica Et Biophysica Acta|May 8, 2009
Pathway analysis of senescence-associated miRNA targets reveals common processes to different senescence induction mechanismsKyle Lafferty-Whyte, Claire J Cairney, Nigel B Jamieson, et al.
Cancer Research|September 17, 2005
Synthetic anticancer gene medicine exploits intrinsic antitumor activity of cationic vector to cure established tumorsChristine Dufès, W Nicol Keith, Alan Bilsland, et al.
Pageof 7

Showing results (11-20 of 61) with videos related to

Sort By:
Pageof 7
Nature Clinical Practice. Oncology|November 3, 2005
Drug insight: Cancer cell immortality-telomerase as a target for novel cancer gene therapiesW Nicol Keith, Alan Bilsland, Maryon Hardie, et al.
Expert Reviews in Molecular Medicine|February 28, 2004
Telomerase-directed molecular therapeuticsW Nicol Keith, Alan Bilsland, T R Jeffry Evans, et al.
Cancer Research|September 6, 2005
Lack of telomerase gene expression in alternative lengthening of telomere cells is associated with chromatin remodeling of the hTR and hTERT gene promotersStuart P Atkinson, Stacey F Hoare, Rosalind M Glasspool, et al.
Cancer Research|February 3, 2006
Transcriptional repression of telomerase RNA gene expression by c-Jun-NH2-kinase and Sp1/Sp3Alan E Bilsland, Katrina Stevenson, Stuart Atkinson, et al.
Oncogene|July 2, 2003
Profiling, comparison and validation of gene expression in gastric carcinoma and normal stomachKarin A Oien, J Keith Vass, Ian Downie, et al.
Regenerative Medicine|May 1, 2007
Telomerase promoter reprogramming and interaction with general transcription factors in the human mesenchymal stem cellNedime Serakinci, Stacey F Hoare, Moustapha Kassem, et al.
Neoplasia (New York, N.Y.)|July 23, 2005
The hTERT and hTERC telomerase gene promoters are activated by the second exon of the adenoviral protein, E1A, identifying the transcriptional corepressor CtBP as a potential repressor of both genesRosalind M Glasspool, Sharon Burns, Stacey F Hoare, et al.
Drug Discovery Today|August 21, 2007
Seeding drug discovery: integrating telomerase cancer biology and cellular senescence to uncover new therapeutic opportunities in targeting cancer stem cellsW Nicol Keith, Catherine M Thomson, Jill Howcroft, et al.
Biochimica Et Biophysica Acta|May 8, 2009
Pathway analysis of senescence-associated miRNA targets reveals common processes to different senescence induction mechanismsKyle Lafferty-Whyte, Claire J Cairney, Nigel B Jamieson, et al.
Cancer Research|September 17, 2005
Synthetic anticancer gene medicine exploits intrinsic antitumor activity of cationic vector to cure established tumorsChristine Dufès, W Nicol Keith, Alan Bilsland, et al.
Pageof 7